Introduction to Cancer Biology (Part 1): Abnormal Signal Transduction

This animation is the first part of the series “An Introduction to Cancer Biology”, and also clarifies the device of irregular signal transduction leading to uncontrolled cell proliferation. This computer animation likewise gives a summary of the potential targets of anticancer treatments.

REFERENCES:
1. Hanahan D, Weinberg RA. The characteristics of cancer cells. Cell. 2000 Jan 7; 100( 1 ):57 -70.

Review of skin growth element receptor biology. Int J Radiat Oncol Biol Phys.

3. Gerharz CD, Ramp U, Reinecke P, et al. Evaluation of growth factor-dependent signalling in human epithelioid sarcoma cell lines. Ideas to the function of autocrine, paracrine and also juxtacrine interactions in epithelioid sarcoma. Eur J Cancer. 2000 Jun; 36( 9 ):1171 -9.

Potapova O, Fakhrai H, Mercola D. Growth factor PDGF-B/v-sis confers a tumorigenic phenotype to human lump cells birthing PDGF receptors yet not to cells devoid of receptors: evidence for an autocrine, yet not a paracrine, mechanism. Int J Cancer.

Skin growth aspect receptor moderates boosted cell spreading, movement, and aggregation in esophageal keratinocytes in vitro and also in vivo. J Biol Chem.

6. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA. When overexpressed in NIH/3T3 cells, erbb-2 is a powerful oncogene. Science. 1987 Jul 10; 237( 4811 ):178 -82.

Skin development factor ligand-independent, unregulated, cell-transforming potential of a naturally happening human mutant EGFRvIII gene. Cell Growth Differ.

Egeblad M, Mortensen OH, Jaattela M. Truncated ErbB2 receptor improves ErbB1 signaling as well as causes reversible, ERK-independent loss of epithelial morphology. Int J Cancer.

9. Lage A, Crombet T, González G. Targeting epidermal growth factor receptor signaling: early results and future patterns in oncology. Ann Med. 2003; 35( 5 ):327 -36.

10. Adjei AA, Hidalgo M. Intracellular signal transduction pathway proteins as targets for cancer cells therapy. J Clin Oncol. 2005 Aug 10; 23( 23 ):5386 -403.

Raf: a calculated target for restorative development versus cancer. J Clin Oncol.

12. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell. 2000 Oct 13; 103( 2 ):253 -62.

13. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001 Feb; 2( 2 ):127 -37.

14. Igney FH, Krammer PH. Death as well as anti-death: tumor resistance to apoptosis. Nat Rev Cancer. 2002 Apr; 2( 4 ):277 -88.

Delhalle S, Duvoix A, Schnekenburger M, Morceau F, Dicato M, Diederich M. An intro to the molecular devices of apoptosis.

Chemoresistance: influence of nuclear variable (NF)-kappaB restraint by tiny conflicting RNA. Clin Cancer Res.

17. Foo P. Metastasis: The trip of mobile cancer cells. Harvard Science Review. Spring 2002; 30-2.

18. Hicklin DJ, Ellis LM. Function of the vascular endothelial growth variable path in tumor growth as well as angiogenesis. J Clin Oncol. 2005 Feb 10; 23( 5 ):1011 -27.

19. Ellis LM. Epidermal development aspect receptor in lump angiogenesis. Hematol Oncol Clin North Am. 2004 Oct; 18( 5 ):1007 -21.

Bevacizumab plus Irinotecan, Fluorouracil, and also Leucovorin for Metastatic Colorectal Cancer. N Engl J Med.

Activity of SU11248, a multitargeted prevention of vascular endothelial development aspect receptor and also platelet-derived growth aspect receptor, in individuals with metastatic renal cell carcinoma. J Clin Oncol.